Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

CJC-1295 With DAC | ≥99% Pure | Nationwide Peptides

Research-grade CJC-1295 With DAC (long-acting GHRH analog), ≥99% purity, HPLC-MS verified. GMP-synthesized with batch CoA. For Research Use Only. Ships fast.

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

For Research Use Only. Not for Human Use.

CJC-1295 with DAC (Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Lys(Maleimidopropionyl)-NH2) is a modified analog of growth hormone-releasing hormone (GHRH 1-29) featuring a Drug Affinity Complex (DAC) attached via a lysine linker at position 30, enabling strong binding to serum albumin for an extended half-life of 5–8 days. This allows sustained, pulsatile GH secretion without the rapid degradation of native GHRH, making it a subject of interest in neuroendocrine research. Developed by ConjuChem Biotechnologies in the mid-2000s, it advanced to Phase II clinical trials before discontinuation due to manufacturing issues. This research-grade lyophilized powder is synthesized under strict quality controls and includes full analytical documentation, making it suitable for in vitro and preclinical research applications.

Key Scientific Attributes

High-purity CJC-1295 with DAC (≥99% by HPLC/MS, acetate salt form)

Verified 30-amino-acid sequence with DAC modification for albumin bioconjugation

Lyophilized formulation for enhanced long-term stability (up to 3 years at -4°F)

Full Certificate of Analysis (COA) with HPLC, MS, amino acid analysis, and endotoxin testing (<0.001 EU/mg)

Manufactured in GMP-aligned, ISO-compliant facilities

Suitable for receptor-binding, pharmacokinetic, and pituitary signaling studies

Research-Referenced Attributes (Based on scientific literature; not intended as therapeutic claims.)

Retains native pulsatile GH secretion profile relative to unmodified GHRH analogs in preclinical models

Subject of preclinical investigations into neuroendocrine signaling and pituitary axis dynamics

Pharmacokinetic profile characterized by extended albumin binding and reduced clearance rate

Relevant to in vitro and preclinical studies of endocrine pathway modeling

Why Researchers Choose CJC-1295 with DAC

Exact clinical-sequence match with DAC modification for authentic pharmacokinetics

Third-party verified purity (>99%) and no fillers (e.g., mannitol-free)

Transparent documentation (HPLC/MS COA, endotoxin-free)

Suitable for use in endocrinology, neuroendocrine, and pituitary biology research settings

Competitive research pricing with bulk options

This product is strictly for laboratory and research purposes only. Not for human or animal use. Not intended to diagnose, treat, cure, or prevent any condition.

Connected topics

Follow this recovery question